About this Research Topic
Despite numerous breakthroughs in basic science, and continuous efforts to translate these discoveries into patients’ clinical benefits, only a handful of advanced therapy medicinal products (ATMPs) have been approved in the past decade. Among those approved, about a third have been pulled from the market and only few have reached appropriate commercial market penetration.
This Research Topic aims to discuss:
(1) key challenges that have hindered the successful translation and commercialisation of ATMPs,
(2) emerging concepts and incentives that fuel the up-and-coming novel ATMPs,
(3) learnings and new ideas that could boost more successes, and
(4) perspectives on key trends that highlight the medium-term evolution of the field of gene-based and cell-based therapies.
Dr. Yves Bayon is a Senior Principal Scientist at Medtronic and Dr. Alain Vertes is affiliated with NxR Biotechnologies GmbH. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
This Research Topic aims to discuss:
(1) key challenges that have hindered the successful translation and commercialisation of ATMPs,
(2) emerging concepts and incentives that fuel the up-and-coming novel ATMPs,
(3) learnings and new ideas that could boost more successes, and
(4) perspectives on key trends that highlight the medium-term evolution of the field of gene-based and cell-based therapies.
Dr. Yves Bayon is a Senior Principal Scientist at Medtronic and Dr. Alain Vertes is affiliated with NxR Biotechnologies GmbH. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Keywords: Advanced therapy medicinal products, regenerative medicine, clinical translation, regulatory landscape, market access, commercialisation of ATMPs
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
